Sitagliptin is an oral antihyperglycemic (antidiabetic drug) of the dipeptidyl
peptidase-4 (DPP-4) inhibitor class. It was developed, and is marketed, by Merck
Easy to read patient leaflet for sitagliptin. Includes indications, proper use, special
instructions, precautions, and possible side effects.
Sep 8, 2016 ... Learn about Januvia (Sitagliptin Phosphate) may treat, uses, dosage, side effects
, drug interactions, warnings, patient labeling, reviews, and ...
JANUVIA works when your blood sugar is high, and works less when your blood
sugar is low, because it works by enhancing your body's own ability to lower ...
May 16, 2007 ... Description, Sitagliptin is a new oral hypoglycemic (anti-diabetic drug) of the new
dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs.
Mar 14, 2016 ... However, because sitagliptin is primarily renally eliminated, severe hepatic
impairment is not expected to affect the pharmacokinetics of ...
Sitagliptin is a pyrazine-derived DIPEPTIDYL-PEPTIDASE IV INHIBITOR and
HYPOGLYCEMIC AGENT that increases the levels of the INCRETIN hormones ...
Sitagliptin is an antidiabetic used to treat diabetes. Read about sitagliptin and it's
side effects and dosage information online at Patient.
Medscape - Diabetes type 2-specific dosing for Januvia (sitagliptin), frequency-
based adverse effects, comprehensive interactions, contraindications, pregnancy
Dec 24, 2014 ... Read about Januvia (sitagliptin), the diabetes medication that reduces blood
sugar levels in individuals with type 2 diabetes.